Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Ficin-Cyclodextrin-Based Docking Nanoarchitectonics of Self-Propelled Nanomotors for Bacterial Biofilm Eradication

  • Ziemyte, Migle
  • Diez-Sánchez, Paula
  • Ferrer, María D.
  • Mira, Alex
  • Escudero-Noguera, Andrea|||0000-0003-2670-6127
  • Murguía, Jose R.|||0000-0001-9364-4603
  • Martí-Centelles, Vicente|||0000-0002-9142-9392
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Development of bioinspired nanomotors showing effective propulsion and cargo delivery capabilities has attracted much attention in the last few years due to their potential use in biomedical applications. However, implementation of this tech-nology in realistic settings is still a barely explored field. Herein, we report the design and application of a multifunctional gated Janus platinum-mesoporous silica nanomotor constituted of a propelling element (platinum nanodendrites) and a drug-loaded nano-container (mesoporous silica nanoparticle) capped with ficin enzyme modified with beta-cyclodextrins (beta-CD). The engineered nanomotor is designed to effectively disrupt bacterial biofilms via H2O2-induced self-propelled motion, ficin hydrolysis of the extracellular polymeric matrix (EPS) of the biofilm, and controlled pH-triggered cargo (vancomycin) delivery. The effective synergic antimicrobial activity of the nanomotor is demonstrated in the elimination of Staphylococcus aureus biofilms. The nanomotor achieves 82% of EPS biomass disruption and a 96% reduction in cell viability, which contrasts with a remarkably lower reduction in biofilm elimination when the components of the nanomotors are used separately at the same concentrations. Such a large reduction in biofilm biomass in S. aureus has never been achieved previously by any conventional therapy. The strategy proposed suggests that engineered nanomotors have great potential for the elimination of biofilms., The authors acknowledge financial support from Project CIPROM/2021/007 from the Generalitat Valenciana. This research was also supported by projects PID2021-126304OB-C41 and PID2021-128141OB-C22 funded by MCIN/AEI/10.13039/501100011033/ and by the European Regional Development Fund - A way of doing Europe. This study was also part of the Advanced Materials Program (MFA/2022/053) supported by MCIN with funding from the European Union NextGenerationEU (PRTR-C17.I1) and by Generalitat Valenciana. This research was also funded by Universitat Politecnica de Valencia and the FISABIO Foundation, NANO-DRILL Project (UGP-19-384), and NANODONT Project (UPV-FISABIO-2020-B14). The authors gratefully acknowledge the support of the European Research Council (ERC) via the Advanced Grant (101052997, EDISON). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council . Neither the European Union nor the granting authority can be held responsible for them. M.Z. thanks for her FPU Ph.D. scholarship by the Spanish government (FPU17/01302). A.E. is also grateful for her Ph.D. grant from the Generalitat Valenciana (ACIF/2018/110). P.D. thanks Instituto de Salud Carlos III and the European Social Fund for financial support "Sara Borrell" (CD20/00120). V.M-C. acknowledges financial support from Project CIDE-GENT/2020/031, funded by Generalitat Valenciana. Scheme 1, (top) and Figure 3a were created with BioRender.com.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Folate- and aCD47-functionalized lipid nanoparticles efficiently deliver mRNA and remodel pancreatic tumor microenvironment

  • Parés, Marta
  • Pallaruelo-Santamaría, Víctor
  • Fillat, Cristina
  • Martínez-Latorre, Javier|||0000-0001-5421-5371
  • Candela-Noguera, Vicente
  • Soriano-Teruel, Paula
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and treatment-resistant malignancies, with limited efficacy to conventional treatments such as surgical resection or chemotherapy. This clinical scenario underscores the need for novel therapeutic strategies. The development of multifunctional platforms capable of targeting tumors through multiple mechanisms offers an innovative strategy to overcome this challenge. Lipid nanoparticles (LNPs) offer a versatile platform capable of efficiently delivering genetic material. Moreover, through surface functionalization it is feasible to improve LNP performance optimizing therapeutic outcomes in a single formulation. Here, we explored a dual functionalization strategy of the LNP for tumor targeting and tumor remodeling to improve treatment efficacy. LNPs were designed for delivering reporter DNA plasmid or mRNA into the PDAC cellular models Capan-2 and PANC-1. The DNA plasmid contains a pancreatic cancer-specific chimeric promoter for transcriptional specificity to PDAC cells. Besides, LNPs were functionalized with folate and an anti-CD47 antibody to both target the folate receptor in PDAC cells and block CD47-mediated immune evasion. Both pDNA and mRNA LNPs targeted PDAC cells in a dose-dependent manner, with mRNA-LNPs demonstrating more efficient transfection. Notably, LNPs functionalized with the anti-CD47 antibody increased phagocytosis in vitro, and promoted an inflammatory phenotype of M1-like macrophages in mouse Capan-2 xenografts. This combinatorial design of the formulated LNP represents an innovative therapeutic strategy and opens future perspectives in the search for effective treatments for PDAC. Keywords: Lipid nanoparticles; Immunotherapy; ACD47; Folate; Macrophages; Pancreatic cancer, This research was supported by European Union s Horizon 2020 research and innovation programme under grant agreement No 899708 (ULISES). The work has also received funding from projects PID2020- 119692RB-C22, PID2023-146637OB-C22, PID2021-128141OBC22, PID2021-126304OB-C41 and PID2024-155683OB-C41 funded by MCIN-Ministerio de Ciencia e Innovacion ¿ and by the European Regional Development Fund A way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012) and (RD21/0017/0012) Instituto de Salud Carlos III, the Generalitat de Catalunya (SGR21/01169). The research leading to these results has also received funding from la Caixa Foundation under agreement LCF/PR/ SP23/52950009. The Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. J.M-L. is grateful to the Spanish MECD for his FPU grant (FPU19/06219). PM.S-T. is grateful to the Generalitat Valenciana for a postdoctoral Investigo contract (INVEST/2023/443). We also acknowledge the support of CERCA Programme/Generalitat de Catalunya.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Spatiotemporal Communication in Artificial Cell Consortia for Dynamic Control of DNA Nanostructures

  • Llopis-Lorente, Antoni|||0000-0002-6987-9506
  • Ventura-Cobos, Jordi|||0000-0001-8475-9820
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Shao, Jingxin
  • Buddingh, Bastiaan C.
  • van Hest, Jan C. M.
  • Abdelmohsen, Loai K. E. A.
[EN] The spatiotemporal orchestration of cellular processes is a ubiquitous phenomenon in pluricellular organisms and bacterial communities, where sender cells secrete chemical signals that activate specific pathways in distant receivers. Despite its importance, the engineering and investigation of spatiotemporal communication in artificial cell consortia remains underexplored. In this study, we present spatiotemporal communication between cellular-scale entities acting as both senders and receivers. The transmitted signals are leveraged to elicit conformational alterations within compartmentalized DNA structures. Specifically, sender entities control and generate diffusive chemical signals, namely, variations in pH, through the conversion of biomolecular inputs. In the receiver population, compartmentalized DNA nanostructures exhibit changes in conformation, transitioning between triplex and duplex assemblies, in response to this pH variation. We demonstrate the temporal regulation of activated DNA nanostructures through the coordinated action of two antagonistic sender populations. Furthermore, we illustrate the transient distance-dependent activation of the receivers, facilitated by sender populations situated at defined spatial locations. Collectively, our findings provide novel avenues for the design of artificial cell consortia endowed with programmable spatiotemporal dynamics through chemical communication., The authors would like to acknowledge the support from the Dutch Ministry of Education, Culture, and Science (Gravitation programs 024.001.035, 024.003.013, 024.005.020 - Interactive Polymer Materials IPM, and the Spinoza premium), ERC Advanced Grant (Artisym 694120), ERC Advanced Grant Edison (101052997), the Spanish Ministry of Science and Innovation, AEI, and FEDER-EU (project PID2021-126304OB-C41), and the GVA (Project CIPROM/2021/007). A.L.-L. acknowledges support from the MSCA Cofund project oLife, which has received funding from the European Union's Horizon 2020 research and innovation program under the Grant Agreement 847675. A.L.-L. thanks the Spanish Government for his "Ramon y Cajal" Fellowship (RYC2021-034728-I), funded by MCIN/AEI/10.13039/501100011033 and by the European Union << NextGenerationEU >>/<< PRTR >>. A.L-L. also thanks the UPV for funding (Ayuda para potenciar la investigacion postdoctoral de la UPV (PAID-PD-22), Ayuda a Primeros Proyectos de Investigacion (PAID-06-22), Vicerrectorado de Investigacion de la Universitat Politecnica de Valencia (UPV)).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Engineering nanoparticle communication in living systems by stigmergy: An application to enhance antitumor therapy in triple-negative breast cancer

  • Estepa-Fernández, Alejandra
  • Lérida-Viso, Araceli
  • Blandez, Juan F.
  • Alfonso-Navarro, María
  • Vivo-Llorca, Gema
  • Orzaez, Mar
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Morella-Aucejo, Ángela|||0000-0002-6357-949X
  • Esteve-Moreno, Juan José|||0000-0002-1259-7663
  • Candela-Noguera, Vicente
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] The engineering of nanoparticle communication has gained growing attention in the last years, however, efforts to communicate nanoparticles with living systems is still a barely studied emerging topic. Here, we explore a nanoparticle cooperation strategy that involves nanoparticle-cell-nanoparticle communication in vivo through stigmergy (a strategy in which nanodevices communicate by modifying the environment). First, mesoporous silica nanoparticles loaded with the senescence inductor palbociclib and coated with a heterobifunctional poly(ethylene glycol) that binds covalently to a MUC1-binding aptamer (NP(palbo)PEG-MUC1), is designed to specifically deliver the pro-senescent drug palbociclib in MDA-MB-231 breast cancer cells. Once the first nanoparticle modifies the environment due to the induction of senescence, a second community of nanoparticles, loaded with the senolytic navitoclax and coated with a hexa-oligo-saccharide (NP(nav)-Gal), releases its cargo to eliminate tumor senescent cells selectively. The targeted therapy through stigmergy communication is tested in vitro, and in vivo, where delays tumor growth and reduces metastases in a mouse model of human triple-negative breast cancer while minimizing undesired drugs side effects., R.M. laboratory members thank the financial support from the Spanish Government projects RTI2018-100910-B-C41 and RTI2018-101599-B-C22 and (MCUI/FEDER, EU) and the Generalitat Valenciana (project PROMETEO 2018/024). This work was funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. This work was supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON). M.O. thanks the financial support from the Spanish Government project (PID2020-115048RB-I0 0) and the Generalitat Valenciana (project PROMETEO/2019/065). A.E-F. is grateful to the Spanish Government for her Ph.D. grant (FPU17/05454), A.L-V. is grateful to the Instituto de Salud Carlos III for her Ph.D. i-PFIS grant (IFI17/00039). J.B. thanks to the Instituto de Salud Carlos III for his Sara Borrell contract (CD19/00038).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

SARS-COV-2 viral RNA detection through oligonucleotide-capped nanoporous anodic alumina supports.

  • López-Palacios, Alba|||0000-0002-4397-277X
  • Caballos-Gómez, María Isabel
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Aznar, Elena|||0000-0003-0361-3876
  • Aranda-Sobrino, María Nieves
  • Calbuig, Eva
  • Gómez-Ruiz, María Dolores
  • Tormo-Mas, M.A.
  • Peman, Javier
  • Climent Terol, Estela
[EN] We describe herein a sensor containing nanoporous anodic alumina (NAA) as sensing platform to identify SARSCOV-2 RNA using a gating mechanism. The system is based on NAA that contains a fluorescent dye (Rhodamine B; RhB) and is capped with an oligonucleotide sequence that hybridize specifically a region of SARS-CoV-2 genome. In the presence of RNA from SARS-COV-2 virus, the oligonucleotide of the surface is displaced, uncapping the pores, and producing a delivery of RhB. The detection of the virus is achieved measuring the fluorescence of the fluorophore. The nanosensor demonstrates to be highly sensitive and selective in aqueous buffers and in biological media, having a limit of detection (LOD) of 50 ± 30 copies mL-1 of SARS-CoV-2 RNA extracted from patients. Moreover, preliminary results using 18 real nasopharyngeal swab samples indicate the potential of the system to differentiate between infected and non-infected patients. Compared to the conventional RT-PCR method, in our system there is no need for sample pretreatment or RNA isolation, providing diagnostic outcomes within 60 mins while maintaining a high level of reliability, This study was sponsored by the Spanish Government (projects PID2021-126304OB-C41 (DOROTHY), PID2021-128141OB-C22 (ANTIVIBEM), and PID2021-122875OB-100 (MCUI/AEI/ FEDER, UE)), the Generalitat Valenciana (project no.2 RD 180/2020, CIPROM/ 2021/007), Supera COVID-19 Fund (DIACOVID project), the Universitat Polit`ecnica de Val`encia&#8722; Instituto de Investigacion ¿ Sanitaria La Fe (IISLaFe) (SARS-COV-2-SEEKER and VISION-COV projects). This research project has received funding from the European Union s HORIZON-CL4- 2022 research and innovation programme under grant agreement ID 101093042, PHOTONGATE project. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor th e granting authority can be held responsible for them. This work was supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON). Also, the project has received funding from the European Union s HORIZON-CL4-2022 research and innovation programme under grant agreement ID 101093042, PHOTONGATE project. A.L.P. thanks the Ministerio de Universidades for his predoctoral grant (FPU20/05297). E. C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086). Scheme 1 was done with BioRender.com. The Medicaments Research Ethics Committee, CEIm of University and Polytechnic La Fe Hospital of Valencia (2021-012-1) approved the use of samples from human patients.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Bi-Functional Topospecific Nanoparticles to Promote Immune-Tumor Cell Engagement as A New Immunotherapeutic Strategy

  • Ortuño-Bernal, Alba Amparo
  • Clara-Trujillo, Sandra|||0000-0002-6455-2993
  • Hicke-García, Francisco Javier|||0000-0002-8419-0467
  • Escudero-Noguera, Andrea|||0000-0003-2670-6127
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Lucena-Sánchez, Elena
  • Pradana-López, Sandra
  • Jiménez-Alduán, Nelia
  • Diez-Sánchez, Paula
[EN] Cancer immunotherapy has emerged as a promising alternative approach, enabling the body's immune system to fight cancer. Cytotoxic T cells play a pivotal role in recognizing and eliminating tumor cells, and their effectiveness relies on establishing a physical interaction and efficient communication with cancer cells. However, this communication is often disrupted by immune escape mechanisms, allowing cancer progression. A versatile nanoplatform is developed to restore cellular connection using Janus mesoporous silica-Au nanoparticle (J-pHLIP-PD1), including specific binding sites on opposite faces for simultaneous binding to cancer cells and immune cells. The two differential surfaces on the nanoparticle allow orthogonal functionalization with the anti-PD-1 antibody that interacts with the PD-1 receptor in cytotoxic T cells on the gold face and the pH Low Insertion Peptide (pHLIP), which undergoes specific insertion into the tumor cell membrane on the silica face. J-pHLIP-PD1 nanoparticles effectively bind the surface of tumor cells and capture T cells, facilitating the formation of immune synapse-like structures that lead to reduced cancer cell viability in vitro, associated with immunogenic cell death signatures. The therapeutic potential of J-pHLIP-PD1 is also demonstrated in an in vivo metastatic melanoma model, where treatment with J-pHLIP-PD1 produces a significant decrease in metastatic burden and increases T cell presence. The Janus nanosystem represents an attractive platform that expands the toolbox of immune-engaging strategies, offering a flexible alternative to conventional immunotherapies that link immune and tumor cells, restoring cell-cell communication for cancer elimination., A. Ortuno-Bernal, S. Clara-Trujillo and E. Lucena-Sanchez have con-tributed equally to this work. This work was supported by the European Research Council (ERC) via Advanced Grant (101052997, EDI-SON). The authors thank the Spanish Government, project PID2021-126304OB-C41 by MCIN/ AEI /10.13039/501100011033/ and by European Regional Development Fund-A way of doing Europe. This studywas also supported by the Generalitat Valenciana (project PROMETEOCIPROM/2021/007). This study forms part of the Advanced Materials pro-gram (MFA/2022/049) and was supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1) and by Generalitat Valenciana. This work was also supported by CIBER -Consorcio Centro deInvestigacion Biomedica en Red- (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. A.G-F. thanks the financial support from FC AECC (IDEAS246782GARC). E.L.-S is grateful for herFPU fellowship funded by MINECO (FPU18/06539). F.J.H thanks MIUfor his FPU grant (FPU20/06021). A.O.B acknowledges support from apredoctoral fellowship funded by the Generalitat Valenciana (GVA, Grant No.CIACIF/2023/320). Samples included in this study were provided bythe Biobanco La Fe (B.0000723) and they were processed following stan-dard operating procedures with the appropriate approval of the Ethics andScientific Committees. Graphical images and schemes were created withBioRender.com.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Development and validation of novel senolytic strategies for targeting and eliminating senescent cells

  • Escriche Navarro, Blanca
[ES] Esta tesis doctoral titulada "Desarrollo y validación de nuevas estrategias senolíticas para la selección y eliminación de células senescentes" se centra en el diseño, síntesis y validación de nanodispositivos y profármacos para eliminar células senescentes, con el objetivo de tratar enfermedades relacionadas con el envejecimiento y el cáncer. En el primer capítulo experimental, presentamos un nanodispositivo para eliminar selectivamente células senescentes explotando la actividad enzimática específica del secretoma senescente. Los resultados mostraron que tras la inducción de senescencia en fibroblastos WI-38 proliferantes con radiación ionizante, las células secretan altos niveles de metaloproteinasa de matriz 3 (MMP-3). Basándose en esto, se cargaron MSNs con navitoclax y se recubrieron con un péptido específico de MMP-3 ( "puerta molecular"), obteniendo NPs(Nav)@MMP-3. Los estudios celulares demostraron una liberación preferencial de la carga en células senescentes en comparación con células proliferantes. Además, el tratamiento de células senescentes con NPs(Nav)@MMP-3 indujo una disminución de la viabilidad celular similar a la del navitoclax, mientras que se observó un efecto protector sobre las células proliferantes. Partiendo de estos resultados en el segundo capítulo experimental describimos una nanopartícula para terapia senolítica mediada por células inmunitarias. Para ello, las nanopartículas recubiertas con el péptido específico de MMP-3 se decoraron con la quimioquina CXCL12 (NPs@CXCL12), potenciando el reclutamiento de células inmunitarias al microambiente senescente. Se verificó la liberación progresiva y específica de la proteína CXCL12 en presencia de MMP-3 mediante ensayos de liberación controlada. Posteriormente, se confirmó la capacidad de las nanopartículas para atraer células T Jurkat a un microambiente senescente mediante ensayos de migración. Los resultados revelaron que las NPs@CXCL12 ejercían un efecto quimiotáctico más significativo que la CXCL12 libre. Además, también se evaluó la capacidad de las células asesinas naturales primarias humanas para eliminar WI-38 senescentes, y se monitorizaron sus trayectorias de migración en respuesta a NPs@CXCL12 o CXCL12 libre utilizando un dispositivo de microfuídica. En el capítulo experimental tres, nos centramos en el diseño de un nanodispositivo dirigido al surfaceoma senescente. En concreto, demostramos que la inducción de la senescencia con palbociclib en células de melanoma humano desarrollaba un fenotipo senescente con sobreexpresión de dipeptidil peptidasa-4 (DPP4).Aquí, se cargaron MSNs con navitoclax, se cubrieron con polietilenglicol que contiene disulfuro ("puerta molecular" sensible a redox) y se funcionalizaron con un anticuerpo contra DPP4. La eficacia de las NPs(Nav)@DPP4-PE en la detección y eliminación de células senescentes se validó in vitro e in vivo utilizando un modelo murino de melanoma senescente inducido por palbociclib. El tratamiento redujo significativamente el crecimiento tumoral y eliminó preferentemente las células senescentes. En el cuarto capítulo experimental, investigamos el potencial de la terapia fotodinámica para la detección y eliminación de células senescentes. Para ello, se sintetizó un fotosensibilizador (compuesto 1) basado en boro-dipirrometeno (BODIPY) activado con ß-galactosidasa asociada a senescencia (SA-ß-gal). El compuesto 1 permanece inactivo hasta que la hidrólisis de la galactosa por la enzima SA-ß-gal restaura la emisión de fluorescencia y la generación de oxígeno singlete. La restauración de la fluorescencia, la capacidad de producir especies reactivas de oxígeno y de matar células senescentes en presencia de luz en el compuesto 1 se demostró en modelos de senescencia inducida por terapia in vitro e in vivo. Además, los estudios revelaron que el compuesto 1 desencadena un potente efecto senolítico tras la irradiación de tumores senescentes en modelos de ratón., [CA] Esta tesi doctoral titulada "Desenvolupament i validació de noves estratègies senolítiques per a la selecció i eliminació de cèl·lules senescents" se centra en el disseny, síntesi i validació de nanodispositius i profàrmacs per a eliminar cèl·lules senescents, amb l'objectiu de tractar malalties relacionades amb l'envelliment i el càncer. En el primer capítol experimental, presentem un nanodispositiu per a eliminar selectivament cèl·lules senescents explotantl'activitat enzimàtica específica del secretoma senescent. Els resultats van mostrar que després de la inducció de senescència en fibroblasts WI-38 proliferants amb radiació ionitzant, les cèl·lules secreten alts nivells de metaloproteinasa de matriu 3 (MMP-3). Basant-se en això, es van carregar MSNs amb navitoclax i es van recobrir amb un pèptid específic de MMP-3 ("porta molecular"), obtenint NPs(Nav)@MMP-3. Els estudis cel·lulars van demostrar un alliberament preferencial de la càrrega en cèl·lules senescents en comparació amb cèl·lules proliferants. A més, el tractament de cèl·lules senescents amb NPs(Nav)@MMP-3 va induir una disminució de la viabilitat cel·lular similar a la del navitoclax, mentres que es va observar un efecte protector sobre les cèl·lules proliferants. Partint déstos resultats en el segon capítol experimental descrivim una nanopartícula per teràpia senolítica mediada per cèl·lules immunitàries. Per a això, les nanopartícules recobertes amb el pèptid específic de MMP-3 es van decorar amb la quimioquina CXCL12 (NPs@CXCL12), potenciant el reclutament de cèl·lules immunitàries al microambient senescent. Ees va verificar l'alliberament progressiu i específic de la proteïna CXCL12 de la bastida en presència de MMP-3 mitjançant assajos d'alliberament controlat. Posteriorment, es va confirmar la capacitat de les nanopartícules per a atraure cèl·lules T Jurkat a un microambient senescent mitjançant assajos de migració. Els resultats van revelar que les NPs@CXCL12 exercien un efecte quimiotàctic més significatiu que la CXCL12. A més, també es va avaluar la capacitat de les cèl·lules assassines naturals primàries humanes per a eliminar WI-38 senescents, i es van monitorar les seues trajectòries de migració en resposta a NPs@CXCL12 o CXCL12 utilitzant un dispositiu de microfuidica. En el capítol experimental tres, ens centrem en el disseny d'un nanodispositiu dirigit al surfaceoma senescent. En concret, vam demostrar que la inducció de la senescència amb palbociclib en cèl·lules de melanoma humà presentava un fenotip senescent amb sobreexpresión de dipeptidil peptidasa-4 (DPP4). Basant-se en esta troballa, es van carregar MSNs amb navitoclax, es van cobrir amb polietilenglicol que conté disulfur, ("porta molecular" sensible a redox) i es van funcionalitzar amb un anticòs contra DPP4. L'eficàcia de les NPs(Nav)@DPP4-PE en la detecció i eliminació de cèl·lules senescents es va validar in vitro i in vivo utilitzant un model murin de melanoma senescent induït per palbociclib.El tractament va reduir significativament el creixement tumoral i va eliminar preferentment les cèl·lules senescents, com van indicar els biomarcadores de senescència analitzats. En el quart capítol experimental, investiguem el potencial de la teràpia fotodinámica per a la detecció i eliminació de cèl·lules senescents. Per a això, es va sintetitzar un fotosensibilizador (compost 1) basat en bor-dipirrometeno activat amb ß-galactosidasa associada a senescència (SA-ß-gal). El 1 roman inactiu fins que la hidròlisi de la galactosa per SA-ß-gal restaura l'emissió de fluorescència i la generació d'oxigen singlete. La restauració de la fluorescència, la capacitat de produir espècies reactives d'oxigen i de matar cèl·lules senescents en presència de llum en el 1 es va demostrar en models de senescència induïda per teràpia in vitro i in vivo. A més, els estudis van revelar que el 1 desencadena un potent efecte senolítico després de la irradiació de tumors senescents en models de ratolí., [EN] This PhD thesis entitled "Development and validation of novel senolytic strategies for targeting and eliminating senescent cells" focuses on the design, synthesis, and validation of nanodevices and prodrugs to eliminate senescent cells, to treat diseases related to aging and cancer. In the first experimental chapter, we present a nanodevice to selectively remove senescent cells by exploiting the specific enzymatic activity of the senescent secretome. The results showed that after the induction of senescence in proliferating WI-38 fibroblasts with ionizing radiation, the cells secrete high levels of matrix metalloproteinase-3 (MMP-3). Based on this, MSNs were loaded with navitoclax and coated with a specific peptide; a substrate of MMP-3 (gatekeeper), yielding NPs(Nav)@MMP-3. Cellular studies demonstrated preferential cargo release in senescent cells compared to proliferating cells. Furthermore, treatment of senescent cells with NPs(Nav)@MMP-3 induced a decrease in cell viability similar to that of free navitoclax, while a protective effect on proliferating cells was observed. Building on these results, in the second experimental chapter, we describe a nanoparticle for immune cell-mediated senolytic therapy. To this end, MSNs coated with the specific peptide MMP-3 were decorated with the chemokine CXCL12 (NPs@CXCL12), enhancing immune cells' recruitment to the senescent microenvironment. First, the progressive and specific release of CXCL12 protein from the scaffold in the presence of MMP-3 was verified by controlled release assays. Subsequently, the ability of the nanoparticles to attract Jurkat T cells to a senescent microenvironment was confirmed by migration assays. The results revealed that NPs@CXCL12 exerted a more significant chemotactic effect than free CXCL12. In addition, the ability of human primary natural killer cells to clear senescent WI-38 was also evaluated, and their migration trajectories were monitored in response to NPs@CXCL12 or free CXCL12 using a microfluidic device. In experimental chapter three, we focused on the design of a nanodevice targeting senescent surfaceome. Specifically, the research proved that the induction of senescence with palbociclib in human melanoma cells developed a senescent phenotype characterized by the up-regulated expression of dipeptidyl peptidase 4 (DPP4). Based on this finding, MSNs were loaded with navitoclax, capped with disulfide-containing polyethylene glycol (redox-sensitive gatekeeper) and finally functionalized with an antibody that recognized the DPP4 protein. The efficacy of NPs(Nav)@DPP4-PE in detecting and eliminating senescent cells was validated in vitro and in vivo using a mouse model of palbociclib-induced senescent melanoma. Furthermore, treatment of mice with the DPP4-targeted nanoparticle significantly reduced tumor growth, and preferentially removed senescent cells, as indicated by the senescence biomarkers analyzed. In the fourth experimental chapter, we investigated the potential of photodynamic therapy for the detection and eradication of senescent cells. For this purpose, a boron dipyrromethene-based photosensitizer (BODIPY) activated with senescent-associated ß-galactosidase (SA-ß-gal) (compound 1) was synthesized. Compound 1 contains a galactose moiety bound to a BODIPY, so it remains inactive until galactose hydrolysis by the SA-ß-gal enzyme restores fluorescence emission and singlet oxygen generation. The restoration of fluorescence, the ability to produce reactive oxygen species, and to kill senescent cells in the presence of light in compound 1 was demonstrated in models of therapy-induced senescence in vitro and in vivo. Furthermore, studies in palbociclib-induced senescent melanoma mouse models reveal that the galactose-conjugated photosensitizer triggers a potent senolytic effect upon irradiation of senescent tumors., This research was supported by projects PID2021-126304OB-C41 and PID2021-128141OB-C22 funded by MCIN/ AEI /10.13039/501100011033/ and by EuropeanRegional Development Fund - A way of doing Europe. This study was also supported byGeneralitat Valenciana (CIPROM/2021/007). This research was supported by CIBER(CB06/01/2012), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovación. Thiswork was also supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON). B.E-N. is grateful to the Instituto de Salud Carlos III (ISCIII) for the grant through the project “IFI19/00026”, co-funded by the European Union and the company Senolytic Therapeutics S.L for the support. E.G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her “Margarita Salas” postdoctoral grant (UP2021-036).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Iridium Nanoparticle-Gated Janus Nanomachines for Enzyme-Controlled Drug Delivery

  • Mayol, Beatriz
  • Gonzalez-Jimenez, Marta
  • Sanchez, Alfredo
  • Portela, Susana
  • Pradana-López, Sandra
  • Moreno, Teresa
  • Cai, RuiYuan
  • Martinez-Ruiz, Paloma
  • Martinez-Quiles, Narcisa
  • Diez-Sánchez, Paula
  • Ojeda, Irene
  • Vilela, Diana
  • Villalonga, Reynaldo
  • López-Benet, Carolina
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Controlled drug delivery systems (DDSs) have emerged as a promising alternative to conventional therapies, aiming to optimize drug release profiles and improve therapeutic outcomes while reducing systemic side effects. In this work, iridium-gated Janus nanomachines are proposed as enzyme-regulated platforms for smart and autonomous drug delivery. These hybrid nanostructures consist of mesoporous silica nanoparticles asymmetrically functionalized with gold nanoparticles bearing surface-anchored enzymes on the metallic hemisphere, while the opposite mesoporous face incorporates pH-responsive molecular gates based on aminophenylboronic acid and d-lactose-functionalized iridium nanoparticles, enabling efficient cargo loading and motility behavior. To evaluate nanomachine operation, two enzymatic systems were employed: glucose oxidase (GOx) and a tandem esterase/alcohol oxidase (AOX) system, using spectrophotometric monitoring of the model cargo release. Both platforms exhibited well-defined release kinetics and good correlation between substrate concentration and high selectivity toward their respective inputs. Motility studies revealed the appearance of two particle populations in the presence of glucose or methanol, consistent with enhanced motion driven by catalytic reactions at the iridium nanoparticle surface upon enzymatic hydrogen peroxide generation. Finally, the GOx-based nanomachine loaded with the antitumoral drug doxorubicin (DOXO) demonstrated efficient cellular internalization, preserved biocompatibility, and enhanced antitumoral activity in HeLa cells. Overall, this work reinforces the potential of enzyme-controlled Janus nanomachines as multifunctional platforms integrating autonomous motion and stimulus-responsive drug delivery for advanced therapeutic applications., Financial support from the Spanish Ministry of Economy and Competitiveness (projects CTQ2017-87954-P and PID2021-125723NB-I00), the Spanish Ministry of Science and Innovation (projects CNS2022-135255 and PID2024-155683OB-C41), and the European Research Council (ERC) via Advanced Grant (101052997, EDISON) is gratefully acknowledged. I.O. thanks the financial support from the regional government of Madrid and Complutense University (PR17/24-31938). M.G. also thanks the Public Employment Service (SEPE) and NextGenerationEU funds for financial support through the Investigo Program (CT19/23-INVM-56) and the Community of Madrid and the European Social Fund Plus (ESF+) CT3/25/PEJ-2024-AI/BIO-32377. T.M. also thanks the Spanish Ministry of Education, Vocational Training and Sports for the Collaboration Grant BDNS-764344. P.D. and S.P.-L. thank the Instituto de Salud Carlos III and the European Social Fund for financial support "Miguel Servet" (CP24/00043) and "Sara Borrell" (CD24/00075), respectively. C.L-B also thanks UPV for her predoctoral grant (PAID-01-25).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Targeting the senescent surfaceome through DPP4 antibody-functionalized nanoparticles. An application to cancer therapy

  • Escriche-Navarro, Blanca
  • Garrido-García, Eva María
  • Escudero-Noguera, Andrea|||0000-0003-2670-6127
  • Montoya-Méndez. Isabel |||0009-0003-7755-4853
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Due to the heterogeneity of the senescent phenotype and the lack of a universal biomarker of senescence, the targeting of senescent cells is still an unresolved challenge, and the elimination of senescent cells using specific drugs (senolytics) is still limited in clinical use due to the off-target effects and associated toxicities of current therapeutic strategies. In this study, the induction of senescence in human melanoma cells by palbociclib is found to lead to a senescent phenotype characterized by overexpression of the membrane protein dipeptidyl peptidase 4 (DPP4), previously identified only in ageing contexts. Based on this discovery, a nanoparticle targeting DPP4 overexpression in the senescent surfaceome is designed, synthesized, and characterized to target senescent cancer cells. The nanoparticle based on mesoporous silica is loaded with the senolytic navitoclax, coated with disulfide-containing poly(ethylene glycol) to generate a redox-sensitive gatekeeper (S-S-PEG), and functionalized with an antibody against the DPP4 protein. The ability of the nanoparticles to effectively detect and eliminate senescent cells was confirmed in vitro and in vivo using a mouse model of palbociclib-induced senescent in melanoma. The DPP4-targeted nanoparticle effectively reduces tumor growth and selectively removes senescent cells. Taken together, this study highlights the potential of surfaceome-targeted nanoparticles, as a clinically relevant strategy for improving senolytic therapies., This research was supported by projects PID2021-128141OB-C22 and PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/10.13039/501100011033/and by European Regional Development Fund-A way of doing Europe and by the ERC Advanced Grant Edison (101052997) . This study was also supported by Generalitat Valenciana (CIPROM/2021/007) . This research was supported by CIBER (CB06/01/2012) , Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovacion. B.E-N. is grateful to the Instituto de Salud Carlos III (ISCIII) for the grant through the project "IFI19/00026", co-funded by the European Union and the company Senolytic Therapeutics S.L for the support. E.G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her "Margarita Salas" postdoctoral grant (UP2021-036) .
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Glucose-Fueled Gated Nanomotors: Enhancing In Vivo Anticancer Efficacy via Deep Drug Penetration into Tumors

  • Escudero-Noguera, Andrea|||0000-0003-2670-6127
  • Hicke-García, Francisco Javier|||0000-0002-8419-0467
  • Esteve-Moreno, Juan José|||0000-0002-1259-7663
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Lucena-Sánchez, Elena
  • Pradana-López, Sandra
  • Sanz-Álvarez, Víctor
  • Garrido-Cano, Iris
  • Torres-Ruiz, Sandra
  • Cejalvo, Juan Miguel
  • Diez-Sánchez, Paula
[EN] Bioinspired nano/micromotors with drug delivery capabilities are emerging tools with the promising potential to treat numerous diseases. However, some major challenges must be overcome before reaching real biomedical applications. Above all, it is necessary to design engines that employ biocompatible and bioavailable fuels to induce efficient propulsion in biological environments. In addition, ideal nanomotors should also be capable of delivering the cargo on-command using selected stimuli. To tackle these challenges, we herein present the design and evaluation (both in vitro and in vivo) of a glucose-driven gated Janus nanomotor that performs on-demand anticancer drug delivery to treat solid tumors. The motor's nanoarchitectonics is based on the anisotropic conjunction of catalytic platinum nanodendrites (PtNds) and a mesoporous silica nanoparticle (acting as a nanocontainer for anticancer drug doxorubicin) capped with enzyme glucose oxidase (GOx). Autonomous nanomotor movement is achieved thanks to two catalytic components, GOx and PtNds, in a hybrid cascade reaction: GOx transforms glucose to give H2O2 that is subsequently catalyzed by PtNds into H2O and O2. Besides, gatekeeper moieties (GOx) respond to the presence of intracellular proteases, which induces doxorubicin delivery. Biological experiments with the nanomotor are carried out in cancer cell cultures, three-dimensional (3D) tumor models (spheroids), in vivo and in patient-derived organoids (PDOs). A strong anticancer effect is found and attributed to the synergistic combination glucose-induced propulsion, controlled drug delivery, elimination of glucose (by GOx), ROS production (H2O2 generation by GOx) and hypoxia reduction (O2 generated by PtNds). Taken together, this study advances the engineering of endogenously fueled nanomotors for in vivo operation and provides insights into the application of active particles in cancer therapy toward clinical application., The authors acknowledge the financial support from Project PROMETEO 2018/024 from the Generalitat Valenciana, Project RTI2018-100910-B-C41 and PID2021-126304OB-C41 funded by MCIN/AEI and FEDER, Project MFA/2022/049 from Advanced Materials program funding by European Union NextGenerationEU (PRTR-C17.I1) and the Generalitat Valenciana and the European Research Council (ERC) via Advanced Grant (101052997, EDISON). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. A.E. thanks the Generalitat Valenciana for her PhD grant (ACIF/2018/110). F.J.H. thanks MIU for his FPU grant (FPU20/06021). E.L.-S. is also grateful for her FPU fellowship funded by MINECO (FPU18/06539). P.D. thanks the Instituto de Salud Carlos III and the European Social Fund for financial support "Sara Borrell" (CD20/00120) and Scientific Foundation of the Spanish Association Against Cancer (AECC) for her postdoctoral grant (INVES246470DIEZ). S.P.-L. thanks Investigo program of the Spanish Government funded by NextGenerationEU from the European Union. V.S.-A. thanks MIU for his FPI grant (PRE2022-103714), J.J.E.-M. thanks the AECC Scientific Foundation for his PhD grant (PRDVA21651ESTE). I.G.-C. was funded by Margarita Salas postdoctoral grant (European Union-Next generation EU). J.M.C. was funded by Sociedad Espanola de Oncologia Medica (Juan Rodes-SEOM). The authors are especially thankful to the associations Amunt Contra el Cancer, La Venuseta, Corazon Solidario Contra el Cancer, Mou-te Per Elles, and Asociacion Las Triples. Scheme A and Figures A-i,B-i, A-i, A, A, and A were created with BioRender.com https://BioRender.com/xs7c89a
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Nanodevice-Mediated Immune Cell Recruitment: Targeting Senescent Cells via MMP-3-Responsive CXCL12-Coated Nanoparticles

  • Escriche-Navarro, Blanca
  • Labernadie, Anna
  • Garrido-García, Eva María
  • Clara-Trujillo, Sandra|||0000-0002-6455-2993
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Senescent cells are involved in age-related disorders in different organs and are therapeutic targets for fibrotic and chronic pathologies. Immune-modulating agents, able to enhance senescent cell detection and elimination by endogenous immune cells, have emerged as pharmacological strategies. We report herein a nanoparticle for immune cell-mediated senolytic therapy designed to recruit immune cells in response to specific enzymatic matrix metalloproteinase-3 (MMP-3) activity in the senescence-associated secretory phenotype. For this, mesoporous silica nanoparticles (MSNs) are coated with a peptide substrate of the metalloproteinase MMP-3, and the peptide is decorated with chemokine CXCL12 that enhances immune cell recruitment (NPs@CXCL12). Controlled release studies confirmed the progressive and specific release of CXCL12 in the presence of MMP-3. The ability of immune cell recruitment in response to a senescent microenvironment (senescent WI-38 fibroblasts) is confirmed by Transwell migration assays with green fluorescent Jurkat T-cells, showing NPs@CXCL12 has an enhanced chemotaxis effect toward senescent cells compared to free CXCL12 (2-fold). Moreover, the cytotoxic capacity of human primary natural killer (NK) cells over senescent WI-38 is also confirmed, and their migration trajectories in response to NPs@CXCL12 or free CXCL12 are monitored by using a microfluidic device. Results confirm the ability of NPs@CXCL12 to generate a chemotactic gradient able to attract NK cells. When compared with free CXCL12, the NPs@CXCL12 system showed a reduction of up to 15.56% in the population of NK cells migrating toward free CXCL12 under competitive conditions. This study demonstrates the potential of designing nanoparticles to recruit immune cells under specific responses to eliminate senescent cells. Results confirm that NPs@CXCL12 can effectively establish a chemotactic gradient to attract NK cells., This research was supported by projects PID2021-128141OB-C22 and PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/and by the European Regional Development FundyA way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovacion. A.L. is grateful to the RYC2020/029736/I grant and PID2021-125212OA-I00 project funded by MCIN. B.E-N. is grateful to the Instituto de Salud Carlos III (ISCIII) for the grant through the project "IFI19/00026", cofunded by the European Union and the company Senolytic Therapeutics S.L. for the support. E.G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her "Margarita Salas" postdoctoral grant (UP2021-036).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Quorum sensing communication between lipid-based artificial cells

  • Llopis-Lorente, Antoni|||0000-0002-6987-9506
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Buddingh, Bastiaan C.
  • van Hest, J.C.M.
  • Abdelmohsen, L.K.E.
[EN] Population behavior based on quorum sensing communication is a key property of living microorganisms. Here, we show quorum sensing behavior in an artificial cell population consisting of giant lipid vesicles loaded with sender-receiver machinery (enzymes and responsive biomolecules). Our system allows the examination of the collective output based on cell density, fuel concentration and proximity, which are important factors controlling natural quorum sensing behavior., The authors acknowledge funding from the Dutch Ministry ofEducation, Culture and Science(Gravitation program 024.001.035and Spinoza premium), ERC Advanced Grant Artisym (694120), ERCAdvanced Grant Edison (101052997); the Spanish Ministry ofScience and Innovation, AEI, and FEDER-EU (project PID2021-126304OB-C41), and the GVA (Project CIPROM/2021/007). A. L.-L.thanks the MSCA Cofund project oLife (847675), which has receivedfunding from the EU's Horizon 2020 research and innovationprogram; and the Spanish Ministry of Universities for his MariaZambrano fellowship funded by Next Generation EU from theEuropean Union. Dr W. Altenburg is thanked for supplying GFP.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Models of Chemical Communication for Micro/Nanoparticles

  • Ventura-Cobos, Jordi|||0000-0001-8475-9820
  • Llopis-Lorente, Antoni|||0000-0002-6987-9506
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Abdelmohsen, L.K.E.
  • van Hest, J.C.M.
[EN] Engineering chemical communication between micro/ nanosystems (via the exchange of chemical messengers) is receiving increasing attention from the scientific community. Although a number of micro- and nanodevices (e.g., drug carriers, sensors, and artificial cells) have been developed in the last decades, engineering communication at the micro/nanoscale is a recent emergent topic. In fact, most of the studies in this research area have been published within the last 10 years. Inspired by nature¿where information is exchanged by means of molecules¿the development of chemical communication strategies holds wide implications as it may provide breakthroughs in many areas including nanotechnology, artificial cell research, biomedicine, biotechnology, and ICT. Published examples rely on nanotechnology and synthetic biology for the creation of micro- and nanodevices that can communicate. Communication enables the construction of new complex systems capable of performing advanced coordinated tasks that go beyond those carried out by individual entities. In addition, the possibility to communicate between synthetic and living systems can further advance our understanding of biochemical processes and provide completely new tailored therapeutic and diagnostic strategies, ways to tune cellular behavior, and new biotechnological tools. In this Account, we summarize advances by our laboratories (and others) in the engineering of chemical communication of micro- and nanoparticles. This Account is structured to provide researchers from different fields with general strategies and common ground for the rational design of future communication networks at the micro/nanoscale. First, we cover the basis of and describe enabling technologies to engineer particles with communication capabilities. Next, we rationalize general models of chemical communication. These models vary from simple linear communication (transmission of information between two points) to more complex pathways such as interactive communication and multicomponent communication (involving several entities). Using illustrative experimental designs, we demonstrate the realization of these models which involve communication not only between engineered micro/ nanoparticles but also between particles and living systems. Finally, we discuss the current state of the topic and the future challenges to be addressed., The authors acknowledge funding from the Dutch Ministry of Education, Culture and Science (Gravitation program 024.005.020 and Spinoza premium), ERC Advanced Grant Artisym (694120), ERC Advanced Grant Edison (101052997); the Spanish Ministry of Science and Innovation, AEI, and FEDER-EU (project PID2021-126304OB-C41), and the GVA (Project CIPROM/2021/007). A.L.-L. thanks the Spanish Government for his Ramón y Cajal Fellowship (RYC2021-034728-I), funded by MCIN/AEI/10.13039/501100011033 and by the European Union &#8810;NextGenerationEU&#8811;/&#8810;PRTR&#8811;. A.L-L. also thanks the UPV for funding (Ayuda para potenciar la investigación postdoctoral de la UPV (PAID-PD-22), Ayuda a Primeros Proyectos de Investigación (PAID-06-22), Vicerrectorado de Investigación de la Universitat Politecnica &#768; de Valencia &#768; (UPV)).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Development of Rapid Detection Tests for SARS-CoV-2 and other Pathogens based on Materials with Molecular Gates

  • Caballos-Gómez, María Isabel
[ES] La presente tesis doctoral titulada "Development of rapid detection tests for SARS-CoV-2 and other pathogens based on materials with molecular gates" se centra en el desarrollo de materiales avanzados de detección, diseñados para la identificación rápida de patógenos como SARS-CoV-2, Xylella fastidiosa y Mycobacterium tuberculosis. Para lograr este objetivo general, la investigación se estructura en cuatro metas específicas, las cuales se desarrollan a lo largo de los capítulos de esta tesis. En el primer capítulo, se presenta el desarrollo de un sistema de detección basado en el soporte de alúmina anódica nanoporosa (NAA) combinado con puertas moleculares de ADN complementario para la detección del ADN genómico de Xylella fastidiosa. Este sistema aprovecha estas hebras como agente de bloqueo de los poros de la NAA, lo que permite una detección específica de este patógeno de gran relevancia en ecología y agricultura. En el segundo capítulo se explora la creación de un sistema basado en materiales de alúmina con anticuerpos como puertas moleculares para la detección de Mycobacterium tuberculosis, el patógeno responsable de la tuberculosis. Este dispositivo busca brindar una detección específica mediante la implementación de anticuerpos que actúan como agentes de bloqueo de los poros a la vez que elemento reconocedor en el sistema. El tercer capítulo, aborda el diseño, síntesis y evaluación de los sistemas de NAA funcionalizados con aptámeros para la detección temprana de SARS-CoV-2. El proyecto de investigación se enfoca en obtener una alta sensibilidad y selectividad para identificar el virus, dado su impacto en la salud pública y la importancia de su detección temprana para controlar la propagación del COVID-19. Por último, el cuarto capítulo se desarrolló un novedoso sistema de detección para material genético de SARS-CoV-2, combinando el sistema CRISPR-Cas con el soporte de NAA funcionalizado con ADN de cadena simple. Esta metodología integró la especificidad de CRISPR-Cas con la amplificación de señal de los materiales de NAA, logrando detectar secuencias de oligonucleótidos específicos con alta precisión. Todos los capítulos profundizan en la síntesis y caracterización de estos materiales con puertas moleculares, que se han diseñado para detectar biomoléculas de diferente naturaleza como pueden ser proteínas o secuencias específicas de ADN. Además, se estudian las dinámicas de liberación del indicador encapsulado en los poros en presencia de sus respectivos analitos e interferentes, lo cual es crucial para evaluar la eficiencia y viabilidad práctica de los materiales en aplicaciones reales. Los estudios demuestran cómo la interacción entre el analito y la puerta molecular desplaza a esta última dando lugar a la liberación controlada del colorante, funcionando como una señal medible que confirma la presencia del patógeno. Estos avances en el diseño de sistemas de detección con puertas moleculares representan un importante progreso en los campos de reconocimiento y diagnóstico, ofreciendo métodos rápidos, altamente sensibles, selectivos y adaptables a la detección de un amplio rango de patógenos de importancia en la actualidad., [CA] La present tesi doctoral titulada "Development of rapid detection tests for SARS-CoV-2 and other pathogens based on materials with molecular gates" se centra en el desenvolupament de materials avançats de detecció, dissenyats per a la identificació ràpida de patògens com SARS-CoV-2, Xylella fastidiosa i Mycobacterium tuberculosis. Per a assolir aquest objectiu general, la investigació s'estructura en quatre metes específiques, les quals es desenvolupen al llarg dels capítols d'aquesta tesi. En el primer capítol, es presenta el desenvolupament d'un sistema de detecció basat en el suport d'alúmina anòdica nanoporosa (NAA) combinat amb portes moleculars d'ADN complementari per a la detecció de l'ADN genòmic de Xylella fastidiosa. Aquest sistema aprofita aquestes cadenes com a agent de bloqueig dels porus de la NAA, la qual cosa permet una detecció específica d'aquest patogen de gran rellevància en ecologia i agricultura. En el segon capítol s'explora la creació d'un sistema basat en materials d'alúmina amb anticossos com a portes moleculars per a la detecció de Mycobacterium tuberculosis, el patogen responsable de la tuberculosi. Aquest dispositiu busca proporcionar una detecció específica mitjançant la implementació d'anticossos que actuen com a agents de bloqueig i reconeixement en el sistema. El tercer capítol aborda el disseny, síntesi i avaluació dels sistemes de NAA funcionalitzats amb aptàmers per a la detecció primerenca de SARS-CoV-2. El projecte de recerca se centra en obtindre una alta sensibilitat i selectivitat per a identificar el virus, donat el seu impacte en la salut pública i la importància de la seua detecció primerenca per a controlar la propagació de la COVID-19. Finalment, el quart capítol desenvolupa un innovador sistema de detecció per a material genètic de SARS-CoV-2, combinant el sistema CRISPR-Cas amb el suport de NAA funcionalitzat amb ADN de cadena simple. Aquesta metodologia integra l'especificitat de CRISPR-Cas amb l'amplificació de senyal dels materials de NAA, aconseguint detectar seqüències específiques d'oligonucleòtids amb alta precisió. Tots els capítols profunditzen en la síntesi i caracterització d'aquests materials amb portes moleculars, que s'han dissenyat per a detectar diferents tipus d'analits, des de cèl·lules i proteïnes fins a seqüències específiques d'ADN. A més, s'estudien les dinàmiques d'alliberament de l'indicador encapsulat en els porus en presència dels seus respectius analits, la qual cosa és crucial per a avaluar l'eficiència i viabilitat pràctica dels materials en aplicacions reals. Els estudis demostren com la interacció entre l'analit i la porta molecular desplaça aquesta última, donant lloc a l'alliberament controlat del colorant i funcionant com un senyal mesurable que confirma la presència del patogen. Aquests avanços en el disseny de sistemes de detecció amb portes moleculars representen un important progrés en els camps del reconeixement i diagnòstic, oferint mètodes ràpids, altament sensibles, selectius i adaptables per a la detecció d'un ampli rang de patògens d'importància actual., [EN] This doctoral thesis, titled "Development of rapid detection tests for SARS-CoV-2 and other pathogens based on materials with molecular gates," focuses on the development of advanced detection materials, designed for the rapid identification of pathogens such as SARS-CoV-2, Xylella fastidiosa, and Mycobacterium tuberculosis. To achieve this aim, the research is structured into four specific goals, which are developed throughout the chapters of this thesis. The first chapter presents the development of a detection system based on nanoporous anodic alumina (NAA) combined with complementary DNA molecular gates to detect the genomic DNA of Xylella fastidiosa. This system leverages these DNA strands as pore-blocking agents in the NAA, allowing a specific detection of this pathogen, which is highly relevant in ecology and agriculture. The second chapter explores the development of a system based on alumina materials with antibodies as molecular gates to recognize Mycobacterium tuberculosis, the pathogen responsible for tuberculosis. This device aims to provide specific detection by implementing antibodies that act as blocking and recognition agents in the system. The third chapter addresses the design, synthesis, and evaluation of NAA systems functionalized with aptamers for the early detection of SARS-CoV-2. This research project focuses on achieving high sensitivity and selectivity to identify the virus, given its impact on public health and the importance of early detection to control the spread of COVID-19. Finally, the fourth chapter develops an innovative detection system for SARS-CoV-2 genetic material, combining the CRISPR-Cas system with an NAA support functionalized with single-stranded DNA. This methodology integrates the specificity of CRISPR-Cas with the signal amplification of NAA materials, achieving highly precise detection of specific oligonucleotide sequences. All chapters explore the synthesis and characterization of these gated materials, designed to detect analytes from different nature, from proteins to specific DNA sequences. In addition, the dynamics of the encapsulated indicator release within the pores are studied in the presence of their respective analytes, which is crucial for evaluating the efficiency and practical feasibility of these materials in real-world applications. The studies demonstrate how the interaction between the analyte and the molecular gate displaces the latter, resulting in the controlled release of the dye, acting as a measurable signal that confirms the presence of the pathogen. These advances in the design of detection systems with molecular gates represent a significant step forward in the fields of recognition and diagnostics, offering rapid, highly sensitive, selective, and adaptable methods for detecting a wide range of pathogens of current importance., This research was supported by MCIN/AEI projects PID2021-126304OB-C41 and PID2020-113256RA-I00 funded by MCIN/AEI and by European Regional Development Fund - A way of doing Europe. Also, it is supported by project PDC2022-133576-C21 funded by MCIN/AEI and by European Union Next GenerationEU/ PRTR. Also, this study forms part of the Advanced Materials programme (MFA/2022/049) and was supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1) and by Generalitat Valenciana. This work was supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON). The project leading to this application has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899708. This study was also supported by Generalitat Valenciana (CIPROM/2021/007). The work was also supported by Agència Valenciana de la Innovació (INNVA2-2021-2) and is susceptible to be co-founded by European Union. Part of the equipment used to develop this work was supported by Generalitat Valenciana (IDIFEDER/2021/044) and is susceptible to be co-founded through the Operational Programme of the European Regional Development Fund. I.C. thanks to Instituto de Salud Carlos III her postdoctoral fellowship (IFI21/0008). BioRender.com was used for the elaboration of some of the figures. The authors want to thank the Electron Microscopy Service at the UPV for support. This research was supported by CIBER - Consorcio Centro de Investigación Biomédica en Red- (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells

  • Escriche-Navarro, Blanca
  • Garrido-García, Eva María
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Cellular senescence is implicated in the occurrence and progression of multiple age-related disorders. In this context, the selective elimination of senescent cells, senolysis, has emerged as an effective therapeu- tic strategy. However, the heterogeneous senescent phenotype hinders the discovery of a universal and robust senescence biomarker that limits the effective of senolytic with off-target toxic effects. Therefore, the development of more selective strategies represents a promising approach to increase the specificity of senolytic therapy. In this study, we have developed an innovative nanodevice for the selective elimi- nation of senescent cells (SCs) based on the specific enzymatic activity of the senescent secretome. The results revealed that when senescence is induced in proliferating WI-38 by ionizing radiation (IR), the cells secrete high levels of matrix metalloproteinase-3 (MMP-3). Based on this result, mesoporous silica nanoparticles (MSNs) were loaded with the senolytic navitoclax (Nav) and coated with a specific peptide which is substrate of MMP-3 (NPs(Nav)@MMP-3). Studies in cells confirmed the preferential release of cargo in IR-induced senescent cells compared to proliferating cells, depending on MMP-3 levels. More- over, treatment with NPs(Nav)@MMP-3 induced a selective decrease in the viability of SCs as well as a protective effect on non-proliferating cells. These results demonstrate the potential use of NPs to develop enhanced senolytic therapies based on specific enzymatic activity in the senescent microenvironment, with potential clinical relevance., This research was supported by projects PID2021-126304OBC41 and PID2021-128141OB-C22 funded by MCIN/ AEI /10.13039/501100011033/ and by European Regional Development Fund - A way of doing Europe. This study was also supported by Generalitat Valenciana (CIPROM/2021/007). This research was supported by CIBER (CB06/01/2012), Instituto de Salud Carlos III and Ministerio de Ciencia e Innovación. This work was also supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON). B.E-N. is grateful to the Instituto de Salud Carlos III (ISCIII) for the grant through the project IFI19/00026 , co-funded by the European Union and the company Senolytic Therapeutics S.L for the support. E.G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her Margarita Salas postdoctoral grant (UP2021-036).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

New advanced anti-tumor therapies based on hybrid mesoporous nanodevices

  • Lucena Sánchez, Elena
[ES] La presente tesis doctoral titulada "New advanced anti-tumor therapies based on hybrid mesoporous nanodevices" se centra en el diseño, síntesis, caracterización y evaluación de nuevos nanodispositivos híbridos orgánico-inorgánicos. En concreto, se han desarrollado nanopartículas de sílice mesoporosas (MSNs) y nanopartículas Janus combinando MSNs con platino y con oro con el objetivo de mejorar los tratamientos anti-tumorales. El primer capítulo es una introducción general que incluye una visión global del contexto en el que se enmarca la investigación realizada. En particular, se incluye información básica sobre los diferentes tipos de nanopartículas empleados en esta tesis doctoral, así como la descripción de la enfermedad del cáncer y la aplicación de los nanomateriales como terapia. A continuación, en el segundo capítulo, se presentan los objetivos generales y específicos de esta tesis doctoral. Los capítulos tercero y cuarto describen dos estrategias terapéuticas basadas en el desarrollo de nanopartículas con movimiento para mejorar la terapia antitumoral. Concretamente, en el primer capítulo experimental se presenta un nanodispositivo autopropulsado para la liberación controlada de fármacos en respuesta al glutatión (GSH) intracelular. Éste se basa en nanopartículas tipo Janus compuestas por sílice mesoporosa y oro, funcionalizadas en la parte del oro con la enzima catalasa, cargadas con doxorrubicina y con cadenas de oligo(etilenglicol) (S-S-PEG) unidas por puentes disulfuro en la cara de la sílice. Una vez sintetizado y caracterizado el dispositivo, se confirmó su movimiento y se demostró el funcionamiento de la puerta molecular. Finalmente, la internalización celular y la liberación de doxorrubicina se estudiaron en cultivos celulares. Motivados por los resultados anteriores, en el cuarto capítulo se describe un nuevo nanomotor diseñado como tratamiento antitumoral y similar al anterior. En este caso, la nanopartícula Janus desarrollada está compuesta por una nanopartícula de sílice mesoporosa junto con una de platino, cargada con doxorrubicina y cubierta con S-S-PEG. Al igual que en el trabajo anterior, se consigue la autopropulsión del dispositivo. Además, se obtuvo el perfil cinético de liberación del cargo en respuesta a estímulos y se confirmó su aplicación en cultivos celulares. Los capítulos cinco y seis se centran en una estrategia terapéutica nueva que consiste en potenciar la acción del sistema inmune sobre el tumor para conseguir su eliminación. En el primero de estos capítulos experimentales, se utilizaron nanopartículas MSNs cargadas con el fármaco JQ-1 y un siRNA frente al factor de crecimiento transformante ßeta (TGF-ß) como inmunoterapia. Una vez sintetizadas y caracterizadas, se confirmó la capacidad de estas nanopartículas para llevar a cabo la liberación de los cargos, junto con la disminución en la expresión de PD-L1 y en la producción de TGF-ß. Por último, se confirmó su aplicabilidad al ser capaces de inducir la eliminación de células de melanoma por el sistema inmune. De acuerdo con el último capítulo experimental, se describe un nuevo enfoque inmunoterapéutico basado en la comunicación química. En este caso, empleamos una nanopartícula Janus de oro y sílice funcionalizada con un péptido llamado pHLIP en la cara de sílice y el anticuerpo contra el receptor PD-1 unido a la cara de oro (J-pHLIP-PD1). La membrana de la célula tumoral es decorada por este nanodispositivo y gracias a la exposición del anticuerpo PD-1, se consiguió atrapar a los linfocitos T circulantes, desencadenando la eliminación de células tumorales por el sistema inmunitario. Además, estos resultados se confirmaron en un modelo metastásico B16-F10-Luc con una reducción de nódulos metastáticos. Finalmente, en el capítulo séptimo y octavo, se aborda la discusión general y las conclusiones derivadas de los estudios experimentales presentados en esta tesis doctoral., [CA] Aquesta tesi doctoral titulada "New advanced anti-tumor therapies based on hybrid mesoporous nanodevices" se centra en el disseny, síntesi, caracterització i avaluació de nous nanodispositius híbrids orgànic-inorgànics. En concret, s'han desenvolupat nanopartícules de sílice mesoporoses (MSNs) i nanopartícules Janus combinant MSNs amb platí i amb or per al tractament antitumoral. El primer capítol és una introducció general que inclou una visió global del context on s'emmarca la recerca realitzada. En particular, es presenta informació bàsica sobre les nanopartícules emprades en aquesta tesi doctoral, així com la descripció de la malaltia del càncer i l'aplicació dels nanomaterials com a teràpia. A continuació, al segon capítol, es presenten els objectius generals i específics d'aquesta tesi doctoral. Els capítols tercer i quart descriuen dues estratègies terapèutiques basades en el desenvolupmanet de nanopartícules amb moviment per aconseguir una millora de la terapia antitumoral. Concretament, al primer capítol experimental es presenta un nanodispositiu autopropulsat per a l'alliberament controlat de fàrmacs en resposta al glutatió (GSH) intracel·lular. Aquest es basa en nanopartícules tipus Janus compostes per sílice mesoporosa i or, funcionalitzades a la part de l'or amb l'enzim catalasa, carregades amb doxorrubicina i amb cadenes d'oligo(etilenglicol) (SS-PEG) unides per ponts disulfur a la cara de la sílice. Una vegada sintetitzat i caracteritzat el dispositiu, es va confirmar la seua capacitat de moviment i es va demostrar el funcionament correcte de la porta molecular. Finalment, la internalització cel·lular i l'alliberament de doxorrubicina es van estudiar en cultius cel·lulars. Motivats pels resultats anteriors, al quart capítol es descriu un nanomotor nou dissenyat com a tractament antitumoral i similar a l'anterior. En aquest cas, la nanopartícula Janus desenvolupada està composta per una nanopartícula de sílice mesoporosa juntament amb una de platí, carregada amb doxorrubicina i coberta amb S-S-PEG. Igual que en el treball anterior, s'aconsegueix autopropulsió del dispositiu. A més, es va obtenir el perfil cinètic d'alliberament del càrrec en resposta a estímuls i se'n va confirmar l'aplicació en cultius cel·lulars. Els capítols cinc i sis se centren en una estratègia terapèutica nova que consisteix a potenciar l'acció del sistema immune sobre el tumor per aconseguir-ne l'eliminació. Al primer d'aquests capítols experimentals, es van utilitzar nanopartícules MSNs carregades amb el fàrmac JQ-1 i un siRNA davant del factor de creixement transformant ßeta (TGF-ß) com a immunoteràpia. Un cop sintetitzades i caracteritzades, es va confirmar la capacitat d'aquestes nanopartícules per dur a terme l'alliberament dels càrrecs, juntament amb la disminució de l'expressió de PD-L1 i de la producció de TGF-ß. Finalment, se'n va confirmar l'aplicabilitat en ser capaços d'induir l'eliminació de cèl·lules de melanoma pel sistema immune. D'acord amb el darrer capítol experimental, es descriu un nou enfocament immunoterapèutic basat en la comunicació química. En aquest cas, fem servir una nanopartícula Janus d'or i sílice funcionalitzada amb un pèptid anomenat pHLIP a la cara de sílice i l'anticòs contra el receptor PD-1 unit a la cara d'or (J-pHLIP-PD1). La membrana de la cèl·lula tumoral és decorada per aquest nanodispositiu i gràcies a l'exposició de l'anticòs PD-1, es va aconseguir atrapar els limfòcits T circulants, desencadenant l'eliminació de cèl·lules tumorals pel sistema immunitari. A més, aquests resultats es van confirmar en un model metastàtic B16-F10-Luc amb una reducció de nòduls metastàtics. Finalment, al capítol setè i vuitè, s'aborda la discussió general i les conclusions derivades dels estudis experimentals presentats en aquesta tesi doctoral., [EN] The present PhD thesis entitled "New advanced anti-tumor therapies based on hybrid mesoporous nanodevices" focuses on the design, synthesis, characterization, and evaluation of new hybrid organic-inorganic nanodevices. We have developed mesoporous silica nanoparticles (MSNs) and Janus platinum-MSN and gold-MSN nanoparticles for tumor treatment. The first chapter is a general introduction that includes an overview of the context related to the research developed in this thesis. In particular, it includes basic information about different nanoparticles used in this doctoral thesis along with the description of cancer disease characteristics and the application of nanomaterials as therapy. Next, in the second chapter, the general and specific objectives of this Ph.D. thesis are presented. The third and fourth chapters describe two nanotechnology-based therapeutic strategies based on the development of nanomotors to improve cancer therapy. Specifically, the first experimental chapter presents a self-moving nanodevice for controlled drug release in response to intracellular glutathione (GSH). It is based on Janus gold-mesoporous silica nanoparticles functionalized with the enzyme catalase in the gold face, loaded with doxorubicin and capped with disulfide-linked oligo(ethylene glycol) (S-S-PEG) chains on the silica face. Once synthesized and characterized, the nanosystem motion was confirmed and the proper gating mechanism of the nanodevice was proven. Finally, the cellular uptake and doxorubicin release capacity have been demonstrated in cell cultures. Encouraged by the above results, chapter four describes a similar nanomotor design for antitumor therapy. In this case, the nanoparticle developed is composed of a Janus platinum-mesoporous silica nanoparticle, loaded with doxorubicin, and capped with S-S-PEG. As well as in the previous work, self-propulsion of the nanoparticles was achieved. Moreover, the stimuli-responsive cargo release kinetic profile was obtained and its application was confirmed in cell cultures. Chapters five and six focus on a new therapeutic strategy, empowering the immune system action on tumors to reach tumor cell death. In the first of these experimental chapters, JQ-1 and transforming growth factor-beta (TGF-ß) siRNA-loaded nanoparticles were used as efficient tumor immunotherapy. Once synthesized and characterized, the efficient cargo delivery was accomplished along with the programmed death-ligand 1 (PD-L1) downregulation and TGF-ß silencing. Lastly, its application was confirmed by triggering a specific immunogenic removal of tumor cells in melanoma cells. In chapter six, the development of a new communication-based immunotherapeutic approach is reported. In this case, we employ Janus gold-MSN functionalized with a peptide called pHLIP onto silica face and anti-PD-1 antibody bound to gold face (J-pHLIP-PD1). Tumor cell membrane is decorated by this nanodevice, leaving exposed on the surface PD-1 antibody which catches circulating T lymphocytes. It triggers immune system-induced-tumor leveling. Moreover, J-pHLIP-PD1 treatment-associated reduction of metastatic burden was also proven. Finally, in the seventh and eighth chapter, the general discussion and conclusions derived from the presented experimental studies of this Ph.D. thesis are exposed., The authors thank the Spanish Government (Projects MAT2015-64139-C4-1, AGL2015-70235-C2-2-R, CTQ2014-58989-P, CTQ2015-71936-REDT and CTQ2017-87954-P) and the Generalitat Valencia (PROMETEO/2018/024) for support. The Comunidad de Madrid (IND2017/BMD-7642) is also gratefully acknowledged. The authors thank the Spanish Government (project PID2021-126304OB-C41, (MCUI/FEDER, EU)) and the Generalitat Valenciana (project PROMETEO CIPROM/2021/007). E.L-S is grateful for her FPU fellowship funded by MINECO (FPU18/06539). This work was supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON). This study forms part of the Advanced Materials program (MFA/2022/049) and was supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1) and by Generalitat Valenciana. This work was supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON) and by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Remodeling the tumor immune microenvironment with lipid nanoparticles

  • Martínez-Latorre, Javier|||0000-0001-5421-5371
[ES] Esta tesis doctoral, titulada "Remodelación del microambiente inmunitario tumoral con nanopartículas lipídicas", explora el desarrollo de nuevas estrategias inmunoterapéuticas contra el cáncer, tanto a nivel terapéutico como de métodos de administración. En concreto, el trabajo investiga enfoques alternativos y relativamente poco explorados, como las inmunoterapias basadas en macrófagos y la inmunoterapia mediada por antígenos exógenos, que tratan de superar las principales limitaciones de las modalidades inmunoterapéuticas actuales. Paralelamente, la tesis evalúa las nanopartículas lipídicas (LNP) como sistemas de administración de genes no virales para la inmunoterapia. El primer capítulo experimental describe el desarrollo de una novedosa plataforma LNP para la inmunoterapia basada en macrófagos. Las LNP cargadas con ADN plasmídico o ARNm de luciferasa se funcionalizaron con ácido fólico (FA) para dirigirse a las células cancerosas pancreáticas que expresan el receptor de folato y con un anticuerpo anti-CD47 (aCD47) para bloquear la evasión inmunitaria mediada por CD47. Los resultados demuestran una transfección eficaz de las células de cáncer de páncreas, con las LNP cargadas con ARNm superando a las formulaciones basadas en plásmidos. Además, la funcionalización con FA mejoró la captación dirigida de LNP in vitro y la funcionalización con aCD47 restauró la fagocitosis de las células tumorales por los macrófagos in vitro. Los experimentos in vivo en modelos de xenoinjertos Capan-2 de ratón con LNP-ARNm-FA-aCD47 demostraron la expresión in vivo de luciferasa y promovieron un cambio hacia un fenotipo de macrófagos proinflamatorio M1 dentro del microambiente tumoral. En conjunto, estos resultados presentan una plataforma LNP optimizada, capaz de inmunomodular los macrófagos asociados a tumores. El segundo capítulo experimental presenta una novedosa inmunoterapia mediada por antígenos exógenos basada en el epítopo alpha-Gal (galactosa-alpha-1,3-galactosa). El epítopo alpha-Gal es altamente inmunogénico en humanos y provoca fuertes respuestas debido a anticuerpos preexistentes. Se desarrollaron LNP que codifican el ARNm de la alpha-1,3-galactosiltransferasa (alpha-GT) para permitir la biosíntesis endógena de alpha-Gal en la superficie de las células tumorales. El tratamiento con estas LNP indujo con éxito la expresión de alpha-Gal en líneas celulares cancerosas murinas y humanas y promovió el reclutamiento de anticuerpos anti-alpha-Gal humanos naturales hacia las células tumorales. Estos resultados identifican a la LNP alpha como una plataforma inmunoterapéutica prometedora que aprovecha la inmunidad humoral preexistente. El tercer capítulo experimental describe una novedosa inmunoterapia mediada por antígenos exógenos basada en la proteína hemaglutinina (H) del virus del sarampión. La proteína H es un antígeno altamente inmunogénico en humanos debido a la vacunación generalizada contra el virus del sarampión. Se formularon LNP que codifican la proteína H y se demostró que transfectan eficazmente tanto cultivos celulares cancerosos bidimensionales como esferoides tumorales tridimensionales. Además, la administración in vivo de LNP H en ratones vacunados contra el sarampión con tumores de melanoma B16-BL6 dio lugar a una disminución significativa del crecimiento tumoral. Este efecto terapéutico está asociado con una fuerte infiltración intratumoral de linfocitos T citotóxicos CD8+, un cambio en la proporción de células T CD8/CD4 y la producción ex vivo de citocinas proinflamatorias tras la reactivación del antígeno, características distintivas de una potente respuesta inmunitaria mediada por células T CD8+. En conjunto, estos resultados ponen de relieve el potencial de LNP H como nueva estrategia para mejorar la inmunogenicidad tumoral y provocar fuertes respuestas inmunitarias antitumorales., [EN] This doctoral thesis, entitled "Remodeling the Tumor Immune Microenvironment with Lipid Nanoparticles", explores the development of novel cancer immunotherapeutic strategies at both the therapeutic and delivery levels. Specifically, the work investigates alternative and comparatively underexplored approaches, including macrophage-based immunotherapies and exogenous antigen-mediated immunotherapy, which seek to overcome key limitations of current immunotherapeutic modalities. In parallel, the thesis evaluates lipid nanoparticles (LNPs) as non-viral gene delivery systems for immunotherapy. The first experimental chapter describes the development of a novel LNP platform for macrophage-based immunotherapy. LNPs loaded with either luciferase-encoding plasmid DNA or mRNA were functionalized with folic acid (FA) for targeting folate receptor-expressing pancreatic cancer cells and with an anti-CD47 antibody (aCD47) to block CD47-mediated immune evasion. The results demonstrate efficient transfection of pancreatic cancer cells, with mRNA-loaded LNPs outperforming plasmid-based formulations. Moreover, the functionalization with FA enhanced targeted uptake of LNPs in vitro and aCD47 functionalization restored the phagocytosis of tumor cells by macrophages in vitro. In vivo experiments in mouse Capan-2 xenograft models with LNP-mRNA-FA-aCD47 demonstrated in vivo expression of luciferase and promoted a shift to a pro-inflammatory, M1-like macrophage phenotype within the tumor microenvironment. Together, these results present an optimized LNP platform capable of immunomodulating tumor-associated macrophages. The second experimental chapter presents a novel exogenous antigen-mediated immunotherapy based on the alpha-Gal epitope (galactose-alpha-1,3-galactose). alpha-Gal epitope is highly immunogenic in humans and elicits strong pre-existing antibody responses. LNPs encoding alpha-1,3-galactosyltransferase (alpha-GT) mRNA were developed to enable endogenous alpha-Gal biosynthesis on tumor cell surfaces. Treatment with these LNPs successfully induced alpha-Gal expression in both murine and human cancer cell lines and promoted the recruitment of naturally occurring human anti-alpha-Gal antibodies to tumor cells. These results identify LNP alpha as a promising immunotherapeutic platform that exploits pre-existing humoral immunity. The third experimental chapter describes a novel exogenous antigen-mediated immunotherapy based on the hemagglutinin (H) protein of the measles virus. H protein is a highly immunogenic antigen in humans due to widespread vaccination against measles virus. LNPs encoding H protein were formulated and shown to efficiently transfect both two-dimensional cancer cell cultures and three-dimensional tumor spheroids. Moreover, in vivo administration of H-expressing LNPs in measles-vaccinated mice bearing B16-BL6 melanoma tumors resulted in significant tumor growth delay. This therapeutic effect is associated with robust intratumoral infiltration of CD8+ cytotoxic T lymphocytes, a shift in the CD8/CD4 T cell ratio, and ex vivo production of pro-inflammatory cytokines upon antigen recall, hallmarks of a potent CD8+ T cell-mediated immune response. Together, these results highlight the potential of LNP H as a novel strategy to enhance tumor immunogenicity and elicit strong antitumor immune responses. We hope that the results obtained in this doctoral thesis will demonstrate the versatility of LNP-based platforms and support the development of innovative cancer immunotherapies that leverage alternative immunotherapeutic strategies, such as macrophage-based approaches and exogenous antigen-mediated immunotherapy., [CA] Esta tesi doctoral, titulada «Remodelació del microambient immunitari tumoral amb nanopartícules lipídiques», explora el desenvolupament de noves estratègies immunoterapèutiques contra el càncer, tant a nivell terapèutic com de mètodes d'administració. En concret, el treball investiga enfocaments alternatius i relativament poc explorats, com les immunoteràpies basades en macròfags i la immunoteràpia mediada per antígens exògens, que tracten de superar les principals limitacions de les modalitats immunoterapèutiques actuals. Paral·lelament, la tesi avalua les nanopartícules lipídiques (LNP) com a sistemes d'administració de gens no virals per a la immunoteràpia. El primer capítol experimental descriu el desenvolupament d'una nova plataforma LNP per a la immunoteràpia basada en macròfags. Les LNP carregades amb ADN plasmídic o ARNm de luciferasa es van funcionalitzar amb àcid fòlic (FA) per a dirigir-se a les cèl·lules canceroses pancreàtiques que expressen el receptor de folat i amb un anticòs anti-CD47 (aCD47) per a bloquejar l'evasió immunitària mediada per CD47. Els resultats demostren una transfecció eficaç de les cèl·lules de càncer de pàncrees, amb les LNP carregades amb ARNm superant a les formulacions basades en plasmidis. A més, la funcionalització amb FA va millorar la captació dirigida de LNP in vitro i la funcionalització amb aCD47 va restaurar la fagocitosi de les cèl·lules tumorals pels macròfags in vitro. Els experiments in vivo en models de xenotrasplantament Capan-2 de ratolí amb LNP-ARNm-FA-aCD47 van demostrar l'expressió in vivo de luciferasa i van promoure un canvi cap a un fenotip de macròfags proinflamatori M1 dins del microambient tumoral. En conjunt, aquests resultats presenten una plataforma LNP optimitzada, capaç de immunomodular els macròfags associats a tumors. El segon capítol experimental presenta una nova immunoteràpia mediada per antígens exògens basada en el epítop alpha-Gal (galactosa-¿-1,3-galactosa). El epítop alpha-Gal és altament immunogènic en humans i provoca fortes respostes a causa d'anticossos preexistents. Es van desenvolupar LNP que codifiquen el ARNm de la ¿-1,3-galactosiltransferasa (¿-GT) per a permetre la biosíntesi endògena de ¿-Gal en la superfície de les cèl·lules tumorals. El tractament amb estes LNP va induir amb èxit l'expressió de ¿-Gal en línies cel·lulars canceroses murines i humanes i va promoure el reclutament d'anticossos anti-¿-Gal humans naturals cap a les cèl·lules tumorals. Estos resultats identifiquen a la LNP alpha com una plataforma immunoterapèutica prometedora que aprofita la immunitat humoral preexistent. El tercer capítol experimental descriu una nova immunoteràpia mediada per antígens exògens basada en la proteïna hemaglutinina (H) del virus de la xarampió. La proteïna H és un antigen altament immunogènic en humans a causa de la vacunació generalitzada contra el virus de la pallola. Es van formular LNP que codifiquen la proteïna H i es va demostrar que transfecten eficaçment tant cultius cel·lulars cancerosos bidimensionals com esferoides tumorals tridimensionals. A més, l'administració in vivo de LNP H en ratolins vacunats contra la pallola amb tumors de melanoma B16-BL6 va donar lloc a una disminució significativa del creixement tumoral. Aquest efecte terapèutic està associat amb una forta infiltració intratumoral de limfòcits T citotòxics CD8+, un canvi en la proporció de cèl·lules T CD8/CD4 i la producció ex vivo de citocines proinflamatòries després de la reactivació de l'antigen, característiques distintives d'una potent resposta immunitària mediada per cèl·lules T CD8+. En conjunt, aquests resultats posen en relleu el potencial de LNP H com a nova estratègia per millorar la immunogenicitat tumoral i provocar fortes respostes immunitàries antitumorals. Esperem que els resultats obtinguts en aquesta tesi doctoral demostren la versatilitat de les plataformes basades en LNP i recolzen el desenvolupament d'immunoteràpies innovadores contra el càncer., This research was supported by European Union’s Horizon 2020 research and innovation programme under grant agreement No 899708 (ULISES). The work has also received funding from projects PID2020-119692RB-C22, PID2023-146637OB-C22, PID2021-128141OBC22, PID2021-126304OB-C41 and PID2024-155683OB-C41 funded by MCIN-Ministerio de Ciencia e Innovación and by the European Regional Development Fund—A way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012) and (RD21/0017/0012) Instituto de Salud Carlos III, the Generalitat de Catalunya (SGR21/01169). The research leading to these results has also received funding from “la Caixa” Foundation under agreement LCF/PR/SP23/52950009. The Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. J.M-L. is grateful to the Spanish MECD for his FPU grant (FPU19/06219). PM.S-T. is grateful to the Generalitat Valenciana for a postdoctoral Investigo contract (INVEST/2023/443). We also acknowledge the support of CERCA Programme/Generalitat de Catalunya.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Smart Nanoparticles for Enhanced Melanoma Therapy: From Controlled Drug Release to Self-Propelled Nanomotors

  • Esteve-Moreno, Juan José|||0000-0002-1259-7663
[ES] La presente tesis doctoral, titulada "Nanopartículas inteligentes para una terapia mejorada contra el melanoma: desde la liberación controlada de fármacos a los nanomotores autopropulsados", se centra en el desarrollo de estrategias terapéuticas innovadoras frente al melanoma mediante nanopartículas inteligentes. En concreto, aborda la síntesis, caracterización y evaluación de nanodispositivos para la liberación controlada de fármacos. Estos sistemas buscan superar barreras características del melanoma, como la evasión inmunitaria, la matriz extracelular tumoral y la degradación prematura de los fármacos, reduciendo los efectos adversos sobre tejidos sanos. El primer capítulo presenta una introducción al cáncer y, especialmente, al melanoma, describiendo sus principales características biológicas, mecanismos de metástasis y evasión inmune. Asimismo, revisa la evolución de las estrategias terapéuticas y las limitaciones que condicionan su eficacia. Posteriormente, se introduce la nanotecnología aplicada a la medicina y sus principales aplicaciones oncológicas. Finalmente, se analizan los sistemas de liberación controlada de fármacos, las profármacos y los estímulos capaces de desencadenar su activación, con especial atención a las nanoestrellas de oro y a las nanopartículas mesoporosas de sílice como plataformas prometedoras para el tratamiento del melanoma. El capítulo segundo se exponen los objetivos de la tesis. El tercer capítulo describe una plataforma nanoterapéutica bioortogonal basada en nanoestrellas de oro para la fotoactivación controlada de profármacos de doxorrubicina mediante luz infrarroja cercana (NIR). Se desarrollaron dos estrategias complementarias: una prodroga de doxorrubicina inactivada mediante grupos 2-nitrobencilo y la misma molécula anclada covalentemente a la superficie de las nanoestrellas. La irradiación NIR induce la liberación controlada de la doxorrubicina activa. Ambas formulaciones mostraron elevada estabilidad en condiciones fisiológicas y activación exclusivamente tras irradiación. Además, se demostró la activación intracelular del profármaco en células de melanoma y cáncer de cuello uterino minimizando los efectos fototérmicos. Los estudios in vitro e in vivo en modelos murinos de melanoma evidenciaron una liberación eficiente del fármaco, una inhibición significativa del crecimiento tumoral y una actividad terapéutica selectiva únicamente bajo irradiación NIR. El cuarto capítulo se centra en el desarrollo de nanomotores autopropulsados para mejorar la distribución de fármacos en regiones profundas del tumor. El sistema se basa en nanopartículas Janus de platino funcionalizadas con lactato oxidasa y cargadas con doxorrubicina. Estas aprovechan el lactato del microambiente tumoral como combustible endógeno, proporcionando propulsión autónoma y depleción metabólica. Los nanomotores mostraron movimiento autónomo y liberación específica del fármaco en condiciones fisiológicas. En células de melanoma produjeron una marcada reducción de la viabilidad celular a bajas concentraciones, mientras que en esferoides tumorales alcanzaron una penetración intratumoral superior a la de sistemas pasivos. Los estudios in vivo demostraron una reducción significativa del tamaño tumoral y un aumento de la infiltración de linfocitos CD8+, sugiriendo una disminución de la evasión inmunitaria asociada al metabolismo del lactato. Finalmente, los capítulos quinto y sexto recogen la discusión general, las perspectivas futuras y las conclusiones. En conjunto, los resultados demuestran la versatilidad de las nanoestrellas plasmónicas y de los nanomotores impulsados por metabolitos como plataformas para terapias antitumorales innovadoras. Estas estrategias combinan activación controlada de profármacos, propulsión autónoma y remodelación del microambiente tumoral para mejorar la administración de fármacos frente al melanoma y otros tumores accesibles., [EN] The present doctoral thesis, entitled "Smart nanoparticles for improved melanoma therapy: from controlled drug release to self-propelled nanomotors", focuses on the development of innovative therapeutic strategies against melanoma through the use of smart nanoparticles. Specifically, it addresses the synthesis, characterization, and evaluation of nanodevices for controlled drug release. These systems are designed to overcome key barriers associated with melanoma, such as immune evasion, the tumor extracellular matrix, and premature drug degradation, while reducing adverse effects on healthy tissues. The first chapter provides an introduction to cancer, and especially to melanoma, describing its main biological features, mechanisms of metastasis, and immune evasion. It also reviews the evolution of therapeutic strategies and the limitations that affect their efficacy. Subsequently, the application of nanotechnology in medicine and its main oncological applications are introduced. Finally, controlled drug delivery systems, prodrugs, and the stimuli capable of triggering their activation are analyzed, with special attention to gold nanostars and mesoporous silica nanoparticles as promising platforms for melanoma treatment. The second chapter presents the objectives of the thesis. The third chapter describes a bioorthogonal nanotherapeutic platform based on gold nanostars for the controlled photoactivation of doxorubicin prodrugs using near-infrared (NIR) light. Two complementary strategies were developed: a doxorubicin prodrug inactivated by 2-nitrobenzyl groups and the same molecule covalently anchored to the surface of the nanostars. NIR irradiation induces the controlled release of active doxorubicin. Both formulations showed high stability under physiological conditions and were activated only upon irradiation. In addition, intracellular activation of the prodrug was demonstrated in melanoma and cervical cancer cells, minimizing photothermal effects. In vitro and in vivo studies in murine melanoma models showed efficient drug release, significant inhibition of tumor growth, and selective therapeutic activity only under NIR irradiation. The fourth chapter focuses on the development of self-propelled nanomotors to improve drug distribution in deep tumor regions. The system is based on platinum Janus nanoparticles functionalized with lactate oxidase and loaded with doxorubicin. These nanoparticles exploit lactate from the tumor microenvironment as an endogenous fuel, providing autonomous propulsion and metabolic depletion. The nanomotors showed self-propulsion and specific drug release under physiological conditions. In melanoma cells, they produced a marked reduction in cell viability at low concentrations, while in tumor spheroids they achieved greater intratumoral penetration than passive systems. In vivo studies demonstrated a significant reduction in tumor size and an increase in CD8+ lymphocyte infiltration, suggesting a decrease in immune evasion associated with lactate metabolism. Finally, the fifth and sixth chapters present the general discussion, future perspectives, and conclusions. Overall, the results demonstrate the versatility of plasmonic nanostars and metabolite-driven nanomotors as platforms for innovative anticancer therapies. These strategies combine controlled prodrug activation, autonomous propulsion, and remodeling of the tumor microenvironment to improve drug delivery against melanoma and other accessible tumors., [CA] La present tesi doctoral, titulada "Nanopartícules intel·ligents per a una teràpia millorada contra el melanoma: des de l'alliberament controlat de fàrmacs fins als nanomotors autopropulsats", se centra en el desenvolupament d'estratègies terapèutiques innovadores contra el melanoma mitjançant l'ús de nanopartícules intel·ligents. En concret, aborda la síntesi, la caracterització i l'avaluació de nanodispositius per a l'alliberament controlat de fàrmacs. Aquests sistemes busquen superar barreres característiques del melanoma, com ara l'evasió immunitària, la matriu extracel·lular tumoral i la degradació prematura dels fàrmacs, reduint els efectes adversos sobre els teixits sans. El primer capítol presenta una introducció al càncer i, especialment, al melanoma, descrivint-ne les principals característiques biològiques, els mecanismes de metàstasi i l'evasió immune. Així mateix, revisa l'evolució de les estratègies terapèutiques i les limitacions que en condicionen l'eficàcia. Posteriorment, s'introdueix la nanotecnologia aplicada a la medicina i les seues principals aplicacions oncològiques. Finalment, s'analitzen els sistemes d'alliberament controlat de fàrmacs, els profàrmacs i els estímuls capaços de desencadenar-ne l'activació, amb una atenció especial a les nanoestrelles d'or i a les nanopartícules mesoporoses de sílice com a plataformes prometedores per al tractament del melanoma. El segon capítol exposa els objectius de la tesi. El tercer capítol descriu una plataforma nanoterapèutica bioortogonal basada en nanoestrelles d'or per a la fotoactivació controlada de profàrmacs de doxorubicina mitjançant llum infraroja pròxima (NIR). Es van desenvolupar dues estratègies complementàries: un profàrmac de doxorubicina inactivat mitjançant grups 2-nitrobenzil i la mateixa molècula ancorada covalentment a la superfície de les nanoestrelles. La irradiació NIR indueix l'alliberament controlat de la doxorubicina activa. Ambdues formulacions van mostrar una elevada estabilitat en condicions fisiològiques i una activació exclusivament després de la irradiació. A més, es va demostrar l'activació intracel·lular del profàrmac en cèl·lules de melanoma i de càncer de coll uterí, minimitzant els efectes fototèrmics. Els estudis in vitro i in vivo en models murins de melanoma van evidenciar un alliberament eficient del fàrmac, una inhibició significativa del creixement tumoral i una activitat terapèutica selectiva únicament sota irradiació NIR. El quart capítol se centra en el desenvolupament de nanomotors autopropulsats per a millorar la distribució de fàrmacs en regions profundes del tumor. El sistema es basa en nanopartícules Janus de platí funcionalitzades amb lactat oxidasa i carregades amb doxorubicina. Aquestes aprofiten el lactat del microambient tumoral com a combustible endogen, proporcionant propulsió autònoma i depleció metabòlica. Els nanomotors van mostrar moviment autònom i alliberament específic del fàrmac en condicions fisiològiques. En cèl·lules de melanoma van produir una reducció marcada de la viabilitat cel·lular a baixes concentracions, mentre que en esferoides tumorals van assolir una penetració intratumoral superior a la dels sistemes passius. Els estudis in vivo van demostrar una reducció significativa de la mida tumoral i un augment de la infiltració de limfòcits CD8+, la qual cosa suggereix una disminució de l'evasió immunitària associada al metabolisme del lactat. Finalment, els capítols cinqué i sisé recullen la discussió general, les perspectives futures i les conclusions. En conjunt, els resultats demostren la versatilitat de les nanoestrelles plasmòniques i dels nanomotors impulsats per metabolits com a plataformes per a teràpies antitumorals innovadores. Aquestes estratègies combinen activació controlada de profàrmacs, propulsió autònoma i remodelació del microambient tumoral per a millorar l'administració de fàrmacs davant del melanoma i altres tumors accessibles., This research was supported by projects PID2021-126304OB-C41, PID2021-128141OB-C22 and PID2024-155683OB-C41, funded by MCIN/AEI/10.13039/501100011033 and by the European Regional Development Fund (ERDF) – A way of doing Europe; by the Generalitat Valenciana (Project PROMETEO CIPROM/2021/007); by Project MFA/2022/049 from the Advanced Materials programme, funded by the European Union NextGenerationEU (PRTR-C17.I1); and by the Generalitat Valenciana and the European Research Council (ERC) via Advanced Grant 101052997 (EDISON). This research was also supported by CIBER – Consorcio Centro de Investigación Biomédica en Red – (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. J.J.E.-M. thanks the AECC Scientific Foundation, and especially the AECC Council of Valencia, for their PhD grant (PRDVA21651ESTE). P.D. thanks the AECC Scientific Foundation for their postdoctoral grant (INVES246470DIEZ). O.F.S. acknowledges the support from the Provincial Council of Gipuzkoa under the Fellows Gipuzkoa programme. F.J.H. thanks MIU for his FPU grant (FPU20/06021). V.S.-A. thanks MIU for his FPI grant (PRE2022-103714). A.G-F. and P.D. thank the Instituto de Salud Carlos III and the European Social Fund for their "Miguel Servet" contracts (CP25/00067 and CP24/00043). The authors thank the UPV Electron Microscopy Service and the CIPF Confocal and Electron Microscopy Services for their technical support. The U26 NMR: Biomedical Applications II platform from NANBIOSIS (ICTS "NANBIOSIS", Research Infrastructures & Services of CIBER-BBN) is also gratefully acknowledged.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Chemical Strategies for the Detection and Elimination of Senescent Cells

  • García-Fleitas, Jessie
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martí-Centelles, Vicente|||0000-0002-9142-9392
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Cellular senescence can be defined as an irreversible stopping of cell proliferation that arises in response to various stress signals. Cellular senescence is involved in diverse physiological and pathological processes in different tissues, exerting effects on processes as differentiated as embryogenesis, tissue repair and remodeling, cancer, aging, and tissue fibrosis. In addition, the development of some pathologies, aging, cancer, and other age-related diseases has been related to senescent cell accumulation. Due to the complexity of the senescence phenotype, targeting senescent cells is not trivial, is challenging, and is especially relevant for in vivo detection in age-related diseases and tissue samples. Despite the elimination of senescent cells (senolysis) using specific drugs (senolytics) that have been shown to be effective in numerous preclinical disease models, the clinical translation is still limited due to the off-target effects of current senolytics and associated toxicities. Therefore, the development of new chemical strategies aimed at detecting and eliminating senescent cells for the prevention and selective treatment of senescence-associated diseases is of great interest. Such strategies not only will contribute to a deeper understanding of this rapidly evolving field but also will delineate and inspire new possibilities for future research.In this Account, we report our recent research in the development of new chemical approaches for the detection and elimination of senescent cells based on new probes, nanoparticles, and prodrugs. The designed systems take advantage of the over-representation in senescent cells of certain biomarkers such as ß-galactosidase and lipofuscin. One- and two-photon probes, for higher tissue penetration, have been developed. Moreover, we also present a renal clearable fluorogenic probe for the in vivo detection of the ß-galactosidase activity, allowing for correlation with the senescent burden in living animals. Moreover, as an alternative to molecular-based probes, we also developed nanoparticles for senescence detection. Besides, we describe advances in new therapeutic agents to selectively eradicate senescent cells using ß-galactosidase activity-sensitive gated nanoparticles loaded with cytotoxic or senolytic agents or new prodrugs aiming to increase the selectivity and reduction of off-target toxicities of current drugs. Moreover, new advances therapies have been applied in vitro and in vivo. Studies with the probes, nanoparticles, and prodrugs have been applied in several in vitro and in vivo models of cancer, fibrosis, aging, and drug-induced cardiotoxicity in which senescence plays an important role. We discuss the benefits of these chemical strategies toward the development of more specific and sophisticated probes, nanoparticles, and prodrugs targeting senescent cells., This work was supported by the European Research Council (ERC) via an Advanced Grant (101052997, EDISON). The authors are also grateful for project PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033 and by the European Regional Development Fund - A way of doing Europe. The authors also thank the Generalitat Valenciana (CIPROM/2021/007). This research was supported by CIBER-Consorcio Centro de Investigación Biomédica en Red (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. J.G.-F. is grateful for her predoctoral Grisolia grant from the Genelalitat Valenciana (GRISOLIAP/2021/ 122). A.B. thanks the MCIN for her BG20/00020 contract. V.M.-C. thanks the Generalitat Valenciana (CIDEGENT/2020/031).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Bioorthogonal Photoactivation of 2-Nitrobenzyl Caged Doxorubicin Anticancer Prodrugs on Gold Nanostars

  • Esteve-Moreno, Juan José|||0000-0002-1259-7663
  • Escudero-Noguera, Andrea|||0000-0003-2670-6127
  • Terrés-Haro, José Manuel|||0000-0001-5794-7332
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Ferreira Silvestre, Óscar
  • Gorbe, Mónica
  • Garrido, Eva
  • Renero-Lecuna, Carlos
  • Langer, Judith
  • Alfonso, María
  • Ibañez, J.
  • Roberto Cao Milán
  • Liz-Marzán, Luis M.
[EN] Bioorthogonal chemistry that can be controlled through near-infrared (NIR) light is a promising route to therapeutics. This study proposes a method to intracellularly photoactivate prodrugs using plasmonic gold nanostars (AuNSt) and NIR irradiation. Two strategies are followed. On one hand, doxorubicin (Dox) masked with a 2-nitrobenzyl carbamate (proDox1) is used as a photoactivatable prodrug. In the second strategy, a photolabile Dox prodrug (proDox2) obtained by modification of Dox with 2-nitrobenzyl diol bearing a disulfide is attached to the AuNSt surface. Under NIR irradiation AuNSt induce local electromagnetic field enhancement, leading to photocleavage of the 2-nitrobenzyl moiety in both proDox1 and proDox2, and subsequent Dox release. Near field enhancement by excitation of surface plasmons in AuNSt is sufficient to record the surface-enhanced Raman scattering (SERS) spectra of proDox1 and proDox2. The therapeutic potential of this bioorthogonal photoactivation strategy is confirmed in vitro and in vivo using a mouse model of human melanoma. NIR-activated AuNSt induce in vivo the intracellular release of Dox and subsequent cancer cell death, thus reducing tumor growth at low irradiation power density to avoid undesired photothermal effects. These results demonstrate that AuNSt are suitable platforms for NIR light-triggered drug delivery in cancer therapy., This research was supported by project PID2021-126304OB-C41 and PID2021-128141OB-C22 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund-A way of doing Europe. The work was also supported by Generalitat Valenciana (CIPROM/2021/007). This study was also supported by the ERC Advanced Grant Edison (101052997). This research was supported by CIBER-Consorcio Centro de Investigacion Biomedica en Red-(CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. J. J. E-M. thanks the financial support from FC AECC and especially to the AECC Council of Valencia for the trust placed (PRDVA21651ESTE). O.F.S. acknowledges the support from the Provincial Council of Gipuzkoa under the program Fellows Gipuzkoa. The authors thank the UPV electron microscopy and CIPF confocal and electron microscopy services for technical support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Chemical Communication between Giant Vesicles and Gated Nanoparticles for Strip-Based Sensing

  • Ventura-Cobos, Jordi|||0000-0001-8475-9820
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Llopis-Lorente, Antoni|||0000-0002-6987-9506
  • Climent Terol, Estela
[EN] Inspired by nature, the development of artificial micro/nanosystems capable of communicating has become an emergent topic in nanotechnology, synthetic biology, and related areas. However, the demonstration of actual applications still has to come. Here, we demonstrate how chemical communication between micro- and nanoparticles can be used for the design of sensing systems. To realize this, we synergistically combine two different types of particles: i.e., giant unilamellar vesicles (GUVs) as senders and gated mesoporous nanoparticles as receivers. The use of engineered GUVs allows the detection of analytes based on responsive membranes, while the use of gated nanoparticles allows a straightforward application on test strips with smartphone-based detection. In addition, we demonstrate that the combined communication system exhibits signal amplification and its application in real samples employing the bacterial toxin ¿-hemolysin as target analyte. Altogether, our report presents a new route for engineering sensing systems based on the combination of communicative micro/nanoparticles., The authors would like to acknowledge the support from ERC Advanced Grant Edison (101052997); the Spanish Ministry of Science and Innovation, AEI, and FEDER-EU (project PID2021-126304OB-C41), and the GVA (Project CIPROM/2021/007). A.L.-L. thanks the Spanish Government for his "Ramon y Cajal" Fellowship (RYC2021-034728-I), funded by MCIN/AEI/10.13039/501100011033 and by the European Union "NextGenerationEU" / "PRTR". A.L-L. also thanks the UPV for funding (Ayuda para potenciar la investigacion postdoctoral de la UPV (PAID-PD-22), Ayuda a Primeros Proyectos de Investigacion (PAID-06-22), Vicerrectorado de Investigacion de la Universitat Politecnica de Valencia (UPV)). E.C. thanks the Instituto de Salud Carlos III for her Miguel Servet Fellowship (CP23/00086).